1)urokinase-plasminogen activator纤溶酶原激活剂抑制因子
英文短句/例句
1.The Changes of the Plasiminogen Activitor Inhibitor-1(PAI-1) in Patients with Coronary Heart Desease and It s Relationship to Clinical Factors;冠心病患者血浆纤溶酶原激活剂抑制因子（PAI-1）的变化及其相关因素的研究
2.Cytokine-induced release of plasminogen activator inhibitor-1 by human pleural mesothelial cells细胞因子诱导人胸膜细胞释放纤溶酶原激活物抑制剂-1的研究
3.Epidermal growth factor differently modulate activity of urokinase plasminogen activator and plasminogen ac-tivator inhibitor-1 in oral squamous cell carcinoma and metastasis carcinoma cell lines外源性表皮生长因子对口腔鳞癌细胞系尿激酶型纤溶酶原激活剂及其抑制剂活性的影响
4.Expression of Plasminogen Activator、Plasminogen Activator Inhibitor in Polycystic Ovary Syndrome纤溶酶原激活、抑制因子在PCOS卵巢中的表达
5.The Study on Relationship between the Expression of Plasminogen Activator, Plasminogen Activator Inhibitors and Invasion and Metastasis in Ovarian Carcinoma;纤溶酶原激活因子及其抑制因子与卵巢癌的浸润转移
6.Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases纤溶酶原激活物抑制剂-1与心血管疾病
7.Inhibitory effect of green tea polyphenols on plasminogen activator inhibitor-1 expression绿茶多酚对纤溶酶原激活物抑制剂-1表达影响
8.The expression of plasminogen activator inhibitor 1 (PAI 1) gene in human astrocytomasG人脑星形细胞瘤纤溶酶原激活抑制因子1基因表达研究
9.Relationship between Sepsis and a 4G/5G Polymorphism Within the Promoter Region of Plasminogen Activator Inhibitor-1 (PAI-1) Gene;纤溶酶原激活物抑制剂-1基因启动子区4G/5G多态性与脓毒症发生发展的相关性
10.The Correlation between 4G/5G Polymorphism in Promoter Region of PAI-1 Gene and Coronary Artery Disease;纤溶酶原激活物抑制剂-1基因启动子区4G/5G多态性与冠心病的关系
11.Levers of von Willebrand factor,type 1 plasminogen activator inhibitor and adiponectin in coronary heart disease patients with hyperglycemia高血糖合并冠心病患者血管性假性血友病因子、纤溶酶原激活剂抑制物及脂联素水平研究
12.Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究
13.The Role of the Plasminogen Activator Inhibitor-1 in the Pathogenesis of Hepatic Fibrosis;纤溶酶原激活物抑制剂-1在肝纤维化发生中的作用
14.Clinical Study of the Expression of Tissue Factor and Urokinase Plasminogen Activator Receptor in Breast Cancer组织因子、尿激酶型纤溶酶原激活剂受体在乳腺癌中的表达
15.Research Progress of Plasminogen Activator Inhibitor One in Gestational Diabetes Mellitus纤溶酶原激活物抑制剂-1（PAI-1）与妊娠期糖尿病的研究
16.Effects of Tang Maiping on Plasminogen Activeator Inhibior in Blood Vessel of Type 2 Diabetic Rats糖脉平对2型糖尿病大鼠血管纤溶酶原激活抑制剂表达的影响
17.Regulation of Plasminogen Activator Inhibitor-1 Expression during 3T3-L1 Adipocytes Differentiation;脂肪细胞分化过程中纤溶酶原激活剂抑制物-1基因的表达调控研究
18.Association of plasminogen activator inhibitor-1 gene promoter 4G/5G genotype polymorphism with gestational diabetes纤溶酶原激活物抑制因子1基因启动子区4G/5G多态性与妊娠糖尿病的相关性研究
相关短句/例句
plasminogen activitor inhibitor-1纤溶酶原激活剂抑制因子-1
1.There is evidence that high plasma plasminogen activitor inhibitor-1 (PAI-1) concentration is associated with the progression of coronary heart disease (CHD) and the development of myocardial infarction.许多证据表明,高血浆浓度的纤溶酶原激活剂抑制因子-1(PAI-1)与冠心病(CHD)的发生发展过程有关,也是心肌梗死发生的重要因素。
3)plasminogen activator inhibitor纤溶酶原激活剂抑制剂
4)Inhibitor of plasminogen activator纤溶酶原激活因子的抑制因子
5)Plasminogen activatorinhibitor type-1组织型纤溶酶原激活因子抑制因子
6)Plasminogen activitor inhibitor纤溶酶原激活因子抑制因子
延伸阅读
纤溶酶原激活剂分子式：CAS号：性质：是一组蛋白酶，使纤溶酶激活生成有活性的纤溶酶。它们主要包括：(1)组织纤溶酶激动剂(tPA)，一种丝氨酸蛋白酶，创伤或应激时从血管内皮释放入血，只有同纤维蛋白结合时才有激活纤溶酶原的活性；(2)尿激酶，对纤维蛋白选择性较低，是某些内皮细胞系合成、经外分泌管道(如肾小管)分泌，可能参与清除沉积在管道内的纤维蛋白；(3)链激酶，临床上用于裂解纤维蛋白，其选择性较差，可作用于液相中的纤溶酶原，也可作用于纤维蛋白血块中的纤溶酶原，链激酶不是蛋白酶，但与纤溶酶原结合成复合物后构象改变，显示蛋白水解酶活性。
